Catalent Can't Duck IP Suit Over Epilepsy Drug Vimpat

By Britain Eakin (November 29, 2021, 8:38 PM EST) -- A Kentucky federal judge on Monday denied a bid to dismiss UCB's suit against Catalent Pharma Solutions over its importation of the active ingredient in anti-epileptic drug Vimpat, saying the complaint plausibly alleges infringement.

U.S. District Judge Gregory F. Van Tatenhove said dismissal is not warranted at this stage of the case. The judge rejected Catalent's argument that UCB Inc. failed to adequately state a claim that Catalent's imports of lacosamide infringe outside of the Hatch-Waxman Act's safe harbor provision, which shields suppliers assisting generic-drug makers developing products for approval with the U.S. Food and Drug Administration.

Judge Van Tatenhove said...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!